BD1.AX - BARD1 Life Sciences Limited

ASX - ASX Delayed price. Currency in AUD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2018
30/06/2017
30/06/2016
Total revenue
-
62
44
-
Cost of revenue
-
-
-
-
Gross profit
-
62
44
-
Operating expenses
Research development
577
771
1,090
-
Selling general and administrative
1,214
1,153
1,302
211
Total operating expenses
2,302
2,104
2,597
2,865
Operating income or loss
-2,302
-2,042
-2,552
-2,865
Interest expense
-
-
-
-
Total other income/expenses net
576
258
-52
-410
Income before tax
-1,717
-1,784
-2,604
-3,271
Income tax expense
0
0
0
0
Income from continuing operations
-1,717
-1,784
-2,604
-3,271
Net income
-1,717
-1,784
-2,604
-3,271
Net income available to common shareholders
-1,717
-1,784
-2,604
-3,271
Reported EPS
Basic
-
-0.00
-0.00
-
Diluted
-
-0.00
-0.00
-
Weighted average shares outstanding
Basic
-
717,142
569,184
-
Diluted
-
717,142
569,184
-
EBITDA
-
-2,042
-2,544
-2,865